ZIM
ALXO icon

Zacks Investment Management’s ALX Oncology ALXO Stock Holding History

Zacks Investment Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,918
Closed -$66.8K – 615
2023
Q3 		$66.8K Buy
+13,918
New +$75.5K ﹤0.01% 590

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Zacks Investment Management's ALXO Position: Q4 2023 in Review

Zacks Investment Management sold out of ALX Oncology (ALXO) in Q4 2023, closing a stake of 13,918 shares — an estimated $66.8K sold.

Zacks Investment Management first reported a position in ALXO in Q3 2023 and held it in 1 quarter. The position peaked at $66.8K in Q3 2023. 93 funds tracked by Wall St. Rank hold ALXO as of Q4 2023.

  • Zacks Investment Management reported no remaining ALX Oncology position as of Q4 2023 after selling out during the quarter.
  • Zacks Investment Management sold 13,918 ALX Oncology shares in Q4 2023, an estimated $66.8K.
  • Zacks Investment Management first reported a position in ALX Oncology in Q3 2023 and held it in 1 quarter.
  • Zacks Investment Management's ALX Oncology position peaked at $66.8K in Q3 2023.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2023.

Based on Zacks Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.